BRAF and RET polymorphism association with thyroid cancer risk, a preliminary study from Khyber Pakhtunkhwa population
CONCLUSION: In conclusion, this study emphasizes the significant association between BRAF polymorphism and thyroid cancer risk, while RET polymorphism showed a less pronounced impact. Further validation using larger and specific datasets is essential to establish conclusive results.PMID:38598020 | DOI:10.1007/s11033-024-09480-y (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - April 10, 2024 Category: Molecular Biology Authors: Maryam Batool Najeeb Ullah Khan Hamza Khan Mikhlid H Almutairi Ijaz Ali Brian D Adams Source Type: research
Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant PD-1 inhibitors: a national cohort study
ConclusionsIrTAE is a common side effect to PD-1 inhibitors primarily occurring within the first 3 months, with a high risk of persistency. Female sex is a strong predictive factor. IrTAE was not associated with improved clinical outcome. (Source: Supportive Care in Cancer)
Source: Supportive Care in Cancer - April 10, 2024 Category: Cancer & Oncology Source Type: research
Bergapten attenuates human papillary thyroid cancer cell proliferation by triggering apoptosis and the GSK-3beta, P13K and AKT pathways
CONCLUSIONS: Our findings emphasize that BG has the potential to be used as a protective natural remedy for human PTC cells.PMID:38591347 | DOI:10.17219/acem/183877 (Source: Cancer Control)
Source: Cancer Control - April 9, 2024 Category: Cancer & Oncology Authors: Jingjing Li Shaik A Hussain Jayasimha R Daddam Mengjie Sun Source Type: research
A Cuproptosis-Related gene Signature as a Prognostic Biomarker in Thyroid Cancer Based on Transcriptomics
Biochem Genet. 2024 Apr 9. doi: 10.1007/s10528-024-10767-9. Online ahead of print.ABSTRACTThyroid cancer (THCA) is the most prevalent endocrine tumor, and its incidence continues to increase every year. However, the processes underlying the aggressive progression of thyroid cancer are unknown. We concentrated on the prognostic and biological importance of thyroid cancer cuproptosis-related genes in this investigation. Genomic and clinical data were obtained from the UCSC XENA website, and cuproptosis-related genes were obtained from the FerrDb website. We performed differential expression analysis and Cox regression analys...
Source: Biochemical Genetics - April 9, 2024 Category: Genetics & Stem Cells Authors: Zirui Guan Hongyong Wang Mingyan Tian Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
A Cuproptosis-Related gene Signature as a Prognostic Biomarker in Thyroid Cancer Based on Transcriptomics
Biochem Genet. 2024 Apr 9. doi: 10.1007/s10528-024-10767-9. Online ahead of print.ABSTRACTThyroid cancer (THCA) is the most prevalent endocrine tumor, and its incidence continues to increase every year. However, the processes underlying the aggressive progression of thyroid cancer are unknown. We concentrated on the prognostic and biological importance of thyroid cancer cuproptosis-related genes in this investigation. Genomic and clinical data were obtained from the UCSC XENA website, and cuproptosis-related genes were obtained from the FerrDb website. We performed differential expression analysis and Cox regression analys...
Source: Biochemical Genetics - April 9, 2024 Category: Genetics & Stem Cells Authors: Zirui Guan Hongyong Wang Mingyan Tian Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
Combined BRAF and PIM1 inhibitory therapy for papillary thyroid carcinoma based on BRAFV600E regulation of PIM1: Synergistic effect and metabolic mechanisms
This study elucidates the role of BRAFV600E in the regulation of PIM1 in PTC and demonstrates the synergistic effect of a novel combination, BRAFi/PIMi, for the treatment of PTC. This discovery, along with the pathways that may be involved in the powerful efficacy of BRAFi/PIMi strategy from the perspective of cell metabolism, provides insight into the molecular basis of PTC progression and offers new perspectives for BRAF-resistant PTC treatment.PMID:38593698 | PMC:PMC11007432 | DOI:10.1016/j.neo.2024.100996 (Source: Neoplasia)
Source: Neoplasia - April 9, 2024 Category: Cancer & Oncology Authors: Qianqian Xu Jiaqi Wang Yuting Mao Ziyang Xuan Ke Yang Xi Tang Xin Zhu Source Type: research
LncRNA HOXA ‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis
In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA-AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these ...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Tijun Xiao An Yan Lifang Tan Hongwei Zhu Wenzhe Gao Source Type: research
Clinical value of ultrasound parameters PI, TTP, and MTT in assessing cervical lymph node metastasis of papillary thyroid carcinoma
CONCLUSION: PI, TTP, and MTT all decrease in PTC patients with CLNM, and TTP has a strong predictor for CLNM in them, with an AUC of 0.855.PMID:38586094 | PMC:PMC10994806 | DOI:10.62347/QWDR4613 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Qingfeng Kong Yangping Yu Qian Qian Hongjun Sun Source Type: research
LncRNA HOXA ‑AS2 is a prognostic and clinicopathological predictor in patients with cancer: A meta‑analysis
In conclusion, elevated expression of lncRNA HOXA-AS2 was significantly related to poor clinical outcomes in various cancer types, such as osteosarcoma, non-small cell lung cancer and papillary thyroid carcinoma, a finding that was further confirmed by the present study. Specifically, the potential of lncRNAHOXA-AS2 as a biomarker in assessing tumor stage, metastasis risk and OS in patients was demonstrated. However, the results of the present study also indicated that the expression of lncRNA HOXA-AS2 was not significantly associated with age or sex, suggesting its role in cancer progression might be independent of these ...
Source: Oncology Letters - April 8, 2024 Category: Cancer & Oncology Authors: Tijun Xiao An Yan Lifang Tan Hongwei Zhu Wenzhe Gao Source Type: research
Clinical value of ultrasound parameters PI, TTP, and MTT in assessing cervical lymph node metastasis of papillary thyroid carcinoma
CONCLUSION: PI, TTP, and MTT all decrease in PTC patients with CLNM, and TTP has a strong predictor for CLNM in them, with an AUC of 0.855.PMID:38586094 | PMC:PMC10994806 | DOI:10.62347/QWDR4613 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - April 8, 2024 Category: Research Authors: Qingfeng Kong Yangping Yu Qian Qian Hongjun Sun Source Type: research
